Previous Article | Next Article 
Journal of Virology, July 2001, p. 5752-5761, Vol. 75, No. 13
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.13.5752-5761.2001
Vaccinia Virus A30L Protein Is Required for
Association of Viral Membranes with Dense Viroplasm To Form
Immature Virions
Patricia
Szajner,1,2
Andrea S.
Weisberg,1
Elizabeth J.
Wolffe,1,
and
Bernard
Moss1,2,*
Laboratory of Viral Diseases, National
Institute of Allergy and Infectious Diseases, National Institutes of
Health, Bethesda, Maryland 20892-0445,1 and
Graduate Program of the Department of Genetics, The George
Washington University, Washington, D.C. 200522
Received 1 March 2001/Accepted 26 March 2001
 |
ABSTRACT |
The previously uncharacterized A30L gene of vaccinia virus has
orthologs in all vertebrate poxviruses but no recognizable nonpoxvirus
homologs or functional motifs. We determined that the A30L gene was
regulated by a late promoter and encoded a protein of approximately 9 kDa. Immunoelectron microscopy of infected cells indicated that the
A30L protein was associated with viroplasm enclosed by crescent and
immature virion membranes. The A30L protein was also present in mature
virions and was partially released by treatment with a nonionic
detergent and reducing agent, consistent with a location in the matrix
between the core and envelope. To determine the role of the A30L
protein, we constructed a stringent conditional lethal mutant with an
inducible A30L gene. In the absence of inducer, synthesis of viral
early and late proteins occurred but the proteolytic processing of
certain core proteins was inhibited, suggesting an assembly block.
Inhibition of virus maturation was confirmed by electron microscopy.
Under nonpermissive conditions, we observed aberrant large, dense,
granular masses of viroplasm with clearly defined margins; viral
crescent membranes that appeared normal except for their location at a
distance from viroplasm; empty immature virions; and an absence of
mature virions. The data indicated that the A30L protein is needed for
vaccinia virus morphogenesis, specifically the association of the dense viroplasm with viral membranes.
 |
INTRODUCTION |
Poxviruses comprise a large family
of complex, double-stranded DNA viruses that replicate in the cytoplasm
of vertebrate or invertebrate cells (17). Vaccinia virus
(VV), the best-characterized member of the family, has a genome of
approximately 190 kbp that encodes nearly 200 proteins. Viral
transcription, DNA replication, and progeny assembly occur in discrete
areas called viral factories that are typically located near the
nucleus of the infected cell. Morphological studies have shown that the
assembly of VV virions proceeds through a series of intermediate stages
(8, 16). The first characteristic viral structure
discernible by electron microscopy is a crescent-shaped membrane with
spicules on the convex surface and electron-dense granular viroplasm in
the concavity. The membrane eventually encloses the granular material
to form a spherical, immature virion (IV) that appears circular in thin section. The IV undergoes further maturation, including condensation of
the viral genome and proteolytic processing of viral core proteins, to
form the infectious brick-shaped intracellular mature virion (IMV). A
double membrane, derived from the trans-Golgi network or
endosomal cisternae (14, 23, 24), wraps some of the IMV to
form the intracellular enveloped virions (IEV). The IEV are transported
to the periphery of the cell, where they can fuse with the plasma
membrane, a process that results in the loss of the outermost membrane
and the formation of extracellular cell-associated enveloped virions
(CEV). Some CEV detach from the cell to form extracellular enveloped
virions (EEV). CEV and EEV are thought to be responsible for
cell-to-cell transmission and long-range viral spread, respectively
(1, 4, 5, 20).
The generation of temperature-sensitive, drug-resistant, and
inducer-dependent conditional lethal mutants has enabled the identification and characterization of many viral proteins involved in
virion assembly. Putative roles for these proteins were deduced from
the stage at which virion assembly was blocked. Thus,
temperature-sensitive mutants with lesions in the F10L serine/threonine
kinase (25, 27) or the H5R phosphoprotein
(11) did not form recognizable viral membranes under
nonpermissive conditions, although viral protein synthesis occurred.
When expression of the membrane protein encoded by the A17L open
reading frame (ORF) was repressed, large granular masses of viroplasm
surrounded by small vesicles or tubules accumulated (21,
30), and neither the characteristic viral membranes nor the IV
formed. Inhibition of A14L expression also resulted in the accumulation
of small vesicles, but in this case there were also aberrant
crescent-like membranes that were detached from the masses of viroplasm
(21, 26). Inhibition of D13L expression (31)
or addition of the drug rifampin (13, 18, 19) led to an
arrest of morphogenesis with the accumulation of masses of viroplasm
coated with irregular membranes that lacked spicules. Using similar
methods, proteins required for later steps in morphogenesis, e.g.,
conversion of IV to IMV and IMV to IEV, were identified.
Transfection experiments, carried out in our laboratory to identify
additional viral proteins required for early steps in virion assembly,
suggested the involvement of a protein encoded by the A30L ORF
(unpublished data of J. Granek, E. J. Wolffe, and B. Moss). In the
present study, we provide the initial characterization of the A30L
protein and evidence that it is involved in the association of the
dense granular viroplasm with viral membranes.
 |
MATERIALS AND METHODS |
Cells and viruses.
BS-C-1 (ATCC CCL6) and HeLa S3 (ATCC
CCL2.2) cells were grown in Eagle's minimal essential medium (EMEM)
and Dulbecco's minimal essential medium, respectively, each obtained
from Quality Biologicals Inc. and supplemented with 10% fetal bovine
serum (FBS). VV strain WR and the recombinant VV (rVV) vT7LacOI were
propagated in HeLa cells as previously described (12). The
rVV vA30Li was replicated in the continuous presence of 50 µM
isopropyl-
-D-thiogalactopyranoside (IPTG) and 2.5% FBS.
All virus stocks were stored at
70°C.
Antibodies.
Antiserum to a peptide corresponding to the
C-terminal 11 amino acids of the predicted A30L ORF preceded by a
cysteine residue (CAASAGREFNRR) was produced in rabbits
(Spring Valley, Woodbine, Md.). The murine monoclonal antibody (MAb)
MHA.11 (BAbCo/Covance, Berkeley, Calif.) recognizes the nine-amino-acid
influenza virus hemagglutinin (HA) epitope tag (YPYDVPDYA).
Nuclease protection assays.
BS-C-1 cells were infected with
VV strain WR at a multiplicity of infection of 10 and harvested at
various times. Total RNA was purified from infected cells using TRIzol
reagent as directed by Life Technologies, Inc. Polyadenylylated mRNA
was isolated from total RNA using a MicroPoly (A) Pure kit according to
the protocol supplied by Ambion Inc. (Austin, Tex.). A DNA fragment containing a bacteriophage T7 promoter attached to a segment
encompassing 89 bp upstream and 112 bp downstream of the A30L putative
transcription initiator element was generated from VV genomic DNA and
the oligonucleotide primers
5'-GGTAATACGACTCACTATAGGGCAATTCATGTACCACGGATAATGTAG-3' and 5'-CGGACAAAGTGTGTAATTGCAGCTTTAC-3' (the T7
promoter sequence is underlined). A radiolabeled riboprobe
complementary to the A30L coding strand was generated by in vitro
transcription using T7 RNA polymerase and [
-32P]UTP
(3,000 Ci/mmol, 10 mCi/ml). A radiolabeled riboprobe complementary to
the F18R gene of VV strain WR (F17R in VV strain Copenhagen) was also
generated by in vitro transcription, using the previously described
pGEM11K plasmid (2) as the template. The radiolabeled riboprobes were gel purified and eluted in 350 µl of 0.5 M ammonium acetate-1 mM EDTA-0.2% sodium dodecyl sulfate (SDS). A 60-ng sample of polyadenylylated mRNA was hybridized overnight with excess radiolabeled riboprobe in 80% deionized formamide-100 mM sodium citrate (pH 6.4)-300 mM sodium acetate (pH 6.4)-1 mM EDTA. Remaining single-stranded RNA was digested with a 1:200 dilution of the nuclease
mixture containing S1 nuclease, RNase A, and RNase T1. Protected fragments were analyzed by electrophoresis in an 8% polyacrylamide-8 M urea gel and visualized by autoradiography.
Plasmids.
To construct pVOTE.1A30L, a complete copy of the
A30L ORF flanked by the NcoI and BamHI
restriction sites at the 5' and 3' ends, respectively, was generated by
PCR using VV genomic DNA as the template and the oligonucleotide
primers 5'-CCCATGGAAGACCTTAACGGGCAAAC-3' and
5'-CGCGGATCCAACGACGATTGAAATTCTCTTCC-3'
(NcoI and BamHI restriction sites are
underlined). The PCR product was digested with BamHI and
NcoI and inserted into pVOTE.1 (28).
To construct pVOTE.1A30L-HA, a complete copy of the A30L ORF containing
an influenza virus HA epitope tag at the C terminus and flanked by the
NcoI and BamHI restriction sites at the 3' and 5'
ends, respectively, was generated by PCR using VV genomic DNA as the
template and the primers
5'-CCCATGGAAGACCTTAACGGGCAAAC-3' and
5'-CCGGATCCTCAAGCATAGTCTGGAACATCATATGGATAACGACGATTGAATTCTCTTCC-3' (NcoI and BamHI restriction sites are
underlined; the sequence corresponding to the HA tag is in italics).
The PCR product was digested with BamHI and NcoI
and inserted into pVOTE.1.
To construct pA30(LF)/gus/A30(RF) for deletion of the A30L ORF, we made
a PCR product containing (i) a complete copy of the
bacterial

-glucuronidase (
gus) gene under the control of the
A30L
promoter and (ii) flanking sequences of the A30L ORF, comprising
a
portion of the A29L ORF (downstream flank) and a complete copy
of the
A31R ORF together with portion of the A32L ORF (upstream
flank). A
902-bp DNA segment corresponding to the downstream-flanking
region of
the A30L ORF (right flank) was generated by PCR using
VV genomic DNA as
the template and the oligonucleotide primers
5'-TGAATAAAATATTTAATATAAACAAAAAGTCGAAAAAGAATTCC-3' and
5'-CGAACCGATGGTATGATTCTAACCTA-3'.
A PCR product containing
the complete
gus gene was generated using
plasmid
pZippy-NEO/GUS, provided by T. Shors, as the template
and the
oligonucleotide primers
5'-GTTTATATTAAATATTTTATTCATTGTTTGCCTCCCTGC-3'
and
5'-ATAATATTTAAATGgTACGTCCTGTAGAAACC-3', in which the
lowercase
letter indicates a point mutation to produce a better Kozak
translation
initiation sequence. An 881-bp DNA segment corresponding to
the
upstream-flanking region of the A30L ORF was generated by PCR
using
VV genomic DNA as the template and the oligonucleotide primers
5'-CAGGACGTAcCATTTAAATATTATATAAACATTTGTG-3' and
5'-CACGTACCAATATTAGGACGGGC-3'.
The final PCR product of
3,597 bp was inserted into the pCR2.1-TOPO
vector (Invitrogen) to
produce plasmid pA30(LF)/gus/A30(RF).
The inserts of all constructs were sequenced by the fluorescence
dideoxy-termination procedure, using an Applied Biosystems
model 310A
genetic
analyzer.
Generation of rVV.
The rVV vA30Li was constructed in two
steps. BS-C-1 cells were infected with vT7LacOI at 1 PFU per cell for
1 h at 37°C. The cells were then washed twice with Opti-MEM I
reduced medium (Life Technologies) and transfected with 2.5 µg of
pVOTE.1A30L, using DOTAP according to the protocol of the manufacturer
(Roche Molecular Biochemicals, Indianapolis, Ind.). After 5 h, the
transfection mixture was removed and replaced with complete EMEM
containing 2.5% FBS. The cells were harvested at 24 h after
infection, and diluted lysates were used to infect BS-C-1 monolayers in
the presence of mycophenolic acid, xanthine, and hypoxanthine to select
for virus expressing xanthine-guanine phosphoribosyltransferase. The infected cells were covered with agar, and mycophenolic acid-resistant plaques were visualized 48 h later with neutral red and picked with a Pasteur pipette. Three successive rounds of plaque purification were performed to isolate the rVV vA30L/A30Li. The presence of the A30L
ORF in the VV HA locus was confirmed by PCR and agarose gel
electrophoresis. vA30L/A30Li was then used to generate vA30Li. BS-C-1
cells were infected with vA30L/A30Li at a multiplicity of 1 and
transfected with 2.5 µg of pA29gusA31 as described above. The lysates
were used to infect BS-C-1 monolayers in the presence of 50 to 100 µM
IPTG. The infected cells were overlaid with agar, incubated for 2 days
at 37°C, and then overlaid with a second layer of agar containing 200 µg of 5-bromo-4-chloro-3-indolyl-
-D-glucuronic acid
(X-Gluc; Clontech Laboratories, Palo Alto, Calif.) per ml. After 2 more
days of incubation, blue plaques containing the rVV expressing
gus were picked and used to infect fresh monolayers of
BS-C-1 cells. In this way, VA30Li was isolated by three consecutive rounds of plaque purification.
The rVV vA30LiHA, containing the influenza virus HA tag at the C
terminus of A30L, was generated by the procedure described
for vA30Li
except that pVOTE.1A30L-HA was used instead of pVOTE.1A30L.
Plaque assay.
BS-C-1 cell monolayers, in six-well tissue
culture plates, were infected with 10-fold serial dilutions of virus.
After 1 h of adsorption, the inocula were removed and replaced
with complete EMEM containing 5% FBS and 0.5% methylcellulose, with
or without IPTG as specified. The infected cells were incubated at
37°C for 2 days, stained with crystal violet, and counted.
One-step virus growth.
BS-C-1 cell monolayers, in six-well
tissue culture plates, were infected with 5 PFU of virus per cell.
After 1 h of adsorption, the inocula were removed and the cell
monolayers were washed twice with complete EMEM containing 2.5% FBS.
The cells were then incubated in complete EMEM containing 2.5% FBS
with or without 50 µM IPTG and harvested at various times after
infection. The infected cells were subjected to three freeze-thaw
cycles, sonicated, and stored at
70°C. Virus titers were determined
by plaque assay in the presence of 50 µM IPTG.
Western blot analysis.
Proteins from infected cell lysates
or purified virions were separated by SDS-polyacrylamide gel
electrophoresis (PAGE). The resolved proteins were electrophoretically
transferred onto a nitrocellulose membrane (Osmonics, Inc.), and the
membrane was blocked overnight in 10% nonfat dried milk in TTBS (100 mM Tris [pH 7.5], 150 mM NaCl, 0.05% [vol/vol] Tween 20). The
membranes were incubated for 1 h with the anti-A30L peptide
polyclonal antibody at a 1:250 dilution, the anti-A14L polyclonal
antibody at a 1:1,000 dilution, or the anti-A10L polyclonal antibody at
a 1:1,000 dilution. The membranes were washed in TTBS and incubated
with anti-rabbit immunoglobulin G (IgG) conjugated to horseradish
peroxidase (Amersham) at a 1:5,000 dilution. Bound IgG was detected
using the SuperSignal West Pico chemiluminescent substrate (Pierce,
Rockford, III.).
Virion extraction.
Purified virus particles were incubated
for 1 h at 37°C in a reaction mixture containing 50 mM Tris-HCl
(pH 7.5) and 1% (vol/vol) NP-40, with or without 50 mM dithiothreitol
(DTT). The insoluble and soluble materials were separated by
centrifugation at 20,000 × g for 30 min at 4°C.
Proteins from the pellet and supernatant were analyzed by
electrophoresis on an SDS-10 to 20% Tris-Tricine polyacrylamide gel
(Invitrogen) followed by Western blotting.
Analysis of [35S]methionine- and
[35S]cysteine-labeled polypeptides by SDS-PAGE.
BS-C-1 cells were infected with either vA30Li or vT7LacOI virus at a
multiplicity of 10 for 1 h at 37°C. The inocula were removed,
and the infected cells were incubated with complete EMEM containing
2.5% FBS, with or without 50 µM IPTG in the case of vA30Li and with
or without 100 µg of rifampin per ml in the case of vT7LacOI. For
pulse-labeling, the cells were incubated with methionine- and
cysteine-free medium containing 2.5% dialyzed FBS (Life Technologies)
and labeled with 100 µCi of [35S]methionine and
[35S]cysteine per ml for 30 min. The cells were then
harvested, washed once with cold phosphate-buffered saline, and
incubated with micrococcal nuclease (0.1 µg/µl) in 10 mM Tris-HCl
(pH 7.5)-10 mM KCl-1 mM CaCl2-0.2% (vol/vol) NP-40-20
mM
-mercaptoethanol-0.2 mM phenylmethylsulfonyl fluoride for 30 min
on ice. The samples were then diluted 1:1 in 0.125 M Tris HCl (pH.
6.8)-4% SDS-20% (vol/vol) glycerol-10% (vol/vol)
-mercaptoethanol-0.004% bromophenol blue. For pulse-chase experiments, the labeling medium was removed and replaced with complete
EMEM containing 2.5% FBS and incubated for 12 h prior to lysis.
The samples were analyzed by electrophoresis on SDS-4 to 20%
polyacrylamide gels (Invitrogen) in Tris-glycine-SDS buffer.
 |
RESULTS |
Transcription of the A30L gene.
Early, intermediate, and late
poxvirus promoters have distinctive sequences (3, 9, 10).
Analysis of the A30L gene revealed the presence of an A+T-rich region
and a TAAATG initiator element typical of a late promoter.
To prove that A30L is a late gene and to precisely locate the
transcription initiation site, a 202-nucleotide RNA probe was made that
was complementary to a DNA segment that included part of the A30L ORF,
the putative TAAAT initiator element, and 89 nucleotides of
upstream sequence. If transcription initiated within the TAAATG
motif, then the A30L mRNA from infected cells would hybridize to
a 112-nucleotide segment of the riboprobe and protect the latter from
nuclease digestion. Initiation of transcription from other sites would
result in protected fragments that were either smaller or larger than
112 nucleotides (Fig. 1A). In the
experiment depicted in Fig. 1B, the uniformly labeled 202-nucleotide
riboprobe was hybridized to polyadenylylated mRNA purified from
mock-infected cells or VV-infected cells at various times after
infection. The RNAs were then treated with nucleases, subjected to gel
electrophoresis, and analyzed by autoradiography. Two bands were
detected when the RNA came from cells that had been infected with VV
for 4 to 24 h (Fig. 1B). The fragment of approximately 112 nucleotides was the size predicted if the RNA initiated within the
TAAATG sequence. The 202-nucleotide fragment corresponded to
the protected full-length riboprobe, presumably derived from
hybridization with transcripts initiated from an upstream gene. No
protection of the probe was observed when the RNA was obtained from
uninfected cells or from cells infected for only 2 h or infected
for 8 h in the presence of the protein synthesis inhibitor
cycloheximide. Both the timing of A30L transcription and the absence of
RNA synthesis in the presence of cycloheximide, which increases the
amounts of early RNAs specifically, were consistent with regulation by
a late promoter. For comparison, a second riboprobe complementary to
the well-characterized F18R late transcript was hybridized to the same
RNA samples. The expected size fragment of 126 nucleotides was produced
with RNA isolated at 4 to 24 h postinfection but not at earlier
times or from cells infected in the presence of cycloheximide, in a
manner similar to that observed for A30L transcription (Fig. 1B). The
results obtained with the nuclease protection assay were confirmed by
Northern blotting using total RNA extracted from VV-infected cells and a uniformly labeled riboprobe complementary to the coding sequence of
the A30L ORF. The riboprobe hybridized to RNAs of different lengths
producing a diffuse band, as expected for the majority of late mRNAs
that do not terminate in a precise manner (data not shown).

View larger version (60K):
[in this window]
[in a new window]
|
FIG. 1.
Transcriptional analysis of the A30L gene. (A) Schematic
diagram of the A30L and adjacent ORFs. Arrows above the ORFs indicate
the predicted locations of the promoters and the directions of
transcription. The dashed arrows below the ORFs represent RNAs that
could be initiated from the A30L or the A32L promoter. The solid bars
below the dashed arrows represent the full-length 202-nucleotide (nt)
riboprobe and the 112-nucleotide segment of the probe that would be
protected from nuclease digestion by hybridization to a mRNA that
initiated at the putative A30L promoter. (B) RNase protection assays of
A30L and F18R transcripts. At the indicated hours postinfection (hpi),
total RNA was extracted from uninfected cells or from VV-infected cells
incubated for various times in the absence or for 8 h in the
presence of cycloheximide (Cx). The polyadenylylated RNA was purified
from each sample and hybridized to uniformly 32P-labeled
RNA probes complementary to the 5' ends and upstream sequences of the
A30L or F18R ORFs. Hybridized samples were digested with a mixture of
RNase T1, RNase A, and S1 nuclease, and the remaining probe
fragments were analyzed by PAGE and autoradiography. The numbers on the
left represent the sizes in nucleotides of 32P-labeled RNA
markers (RNA Century; Ambion). Lane P contained full-length undigested
probe; the remaining lanes contained samples derived from cells mock
infected for 8 h (U) or from cells harvested at 2 through 24 h after infection. The expected positions of the probe fragments
protected by the A30L and F18R transcripts are indicated on the
right.
|
|
Temporal synthesis of the A30L protein.
The A30L ORF was
predicted to encode a protein of 77 amino acids with a predicted mass
of 8.7 kDa. To establish that such a protein is made and to determine
its time of synthesis, total-cell lysates from VV-infected cells were
analyzed by SDS-PAGE followed by Western blotting using an antiserum
raised against the C-terminal 11 amino acids of A30L. A protein
migrating as expected for a mass of approximately 9 kDa was clearly
detected at 8 h after infection and increased in intensity at
later times (Fig. 2). An additional faint
band migrating between the 14.3- and 21.5-kDa markers at 24 h
after infection was noticed but not identified. No difference in the
mobility of the A30L was observed when the protein was analyzed under
nonreducing conditions using the anti-A30L antiserum (data not shown),
consistent with the absence of cysteine residues in the predicted amino
acid sequence.

View larger version (41K):
[in this window]
[in a new window]
|
FIG. 2.
Temporal synthesis of the A30L protein. BS-C-1 cells
were mock infected for 8 h (U) or infected with VV at a multiplicity of
10 in the absence or presence of cytosine arabinoside (AraC) and
harvested between 0 and 24 h postinfection (hpi). Proteins from
total-cell extracts were resolved by electrophoresis on a 10 to 20%
gradient polyacrylamide gel in SDS-Tricine buffer and analyzed by
Western blotting using antiserum directed to the C-terminal 11 amino
acids of the A30L protein. Proteins were detected by chemiluminescence.
The positions of migration and molecular masses of marker proteins are
indicated on the left.
|
|
The A30L protein was not detected when cells were infected with VV in
the presence of the DNA synthesis inhibitor cytosine
arabinoside (AraC)
(Fig.
2), demonstrating a requirement for viral
DNA synthesis that was
consistent with late
expression.
Association of the A30L protein with virions.
The association
of the A30L protein with highly purified virus particles was
demonstrated by SDS-PAGE of sucrose gradient fractions. The peak of
A30L protein, determined by Western blotting (Fig.
3B), coincided with the fractions
containing the most virus particles as determined by measurement of
optical density at 260 nm (data not shown) and by detection of other
virion proteins by silver staining (Fig. 3A).

View larger version (46K):
[in this window]
[in a new window]
|
FIG. 3.
Association of the A30L protein with purified virions.
(A) Purified VV particles were sedimented on a sucrose gradient.
Fractions were collected, and the proteins were resolved by
electrophoresis on an SDS-4 to 20% gradient polyacrylamide gel.
Proteins were visualized by silver staining. The positions of migration
and molecular masses of marker proteins are indicated on the left. (B)
Proteins from the sucrose gradient fractions analyzed in panel A were
separated by electrophoresis on a 10 to 20% gradient polyacrylamide
gel in SDS-Tricine buffer, transferred to a nitrocellulose membrane,
and probed with rabbit polyclonal A30L peptide antibody. The bands
detected by chemiluminescence are shown. (C) Sucrose-gradient purified
VV (108 PFU) was incubated in Tris buffer containing 1%
NP-40 with or without 50 mM DTT. After centrifugation, the soluble (S)
and insoluble (P) fractions were analyzed by SDS-PAGE and Western
blotting using the rabbit polyclonal A30L peptide antiserum, A14L
rabbit polyclonal antibody, or A10L (P4a) rabbit polyclonal antibody as
indicated.
|
|
VV membrane and core proteins can be separated by centrifugation after
treatment of virions with a nonionic detergent. SDS-PAGE
followed by
Western blotting, however, demonstrated that the A30L
protein was only
partially released from the virus particles treated
with either NP-40
alone or NP-40 plus DTT (Fig.
3C). As a control
for the efficiency of
the extraction procedure, the nitrocellulose
membrane that had been
incubated with the anti-A30L antibody was
stripped and reprobed with
antibodies to A14L and A10L (P4a) proteins
(Fig.
3C). As expected, the
A14L membrane protein was completely
extracted with NP-40 plus DTT,
while most of the A10L core protein
remained associated with the
insoluble fraction. The partial extraction
of the A30L protein with
NP-40 and DTT suggested that it might
be located in the matrix between
the core and the
membrane.
Generation of an rVV expressing an inducible copy of A30L.
To
determine the role of A30L in the virus replication cycle, we
constructed an rVV in which the expression of A30L was stringently regulated (Fig. 4A). This rVV was
constructed in two steps. First, the inducible copy of A30L, containing
a bacteriophage T7 promoter, the Escherichia coli lac
operator, and part of the untranslated leader sequence of
encephalomyocarditis virus RNA, was inserted into the HA locus (A56R
ORF) of the previously constructed vT7LacOI recombinant virus
(28). vT7LacOI contains an IPTG-inducible copy of the
bacteriophage T7 RNA polymerase gene and a continuously expressed
E. coli lac repressor gene. The resulting intermediate virus, vA30L/A30Li, contained both endogenous and inducible copies of
A30L. In the second step, the endogenous A30L gene was deleted from the
vA30L/A30Li virus by homologous recombination using a plasmid
containing the gus gene under the control of the A30L promoter. The final recombinant virus, vA30Li, was isolated in the
presence of 50 µM IPTG and identified by the expression of the
gus gene. Another recombinant virus, vA30LiHA, in which the inducible copy of A30L has a C-terminal influenza virus HA tag, was
constructed in a similar manner. The genotypes of both vA30Li and
vA30LiHA were confirmed by PCR.

View larger version (52K):
[in this window]
[in a new window]
|
FIG. 4.
Construction of an A30L-inducible rVV. (A) Schematic
diagram representing the genome of vA30Li. The J2R (thymidine kinase
[TK]), A30L, and A56R (HA) loci are depicted. Insertions into these
loci are shown below the line. Additional abbreviations: P11, a VV late
promoter; P7.5, a VV early-late promoter; lacO, E. coli lac
operator; lacI, E. coli lac repressor gene; T7 pol,
bacteriophage T7 RNA polymerase gene; PT7, bacteriophage T7 promoter;
EMC, encephalomyocarditis virus cap-independent translation enhancer
element; gus, E. coli -glucuronidase gene; gpt, E. coli guanine phosphoribosyltransferase gene. (B) Effect of IPTG on
virus plaque formation. BS-C-1 cell monolayers were infected with
vT7LacOI, vA30L/A30Li, or vA30Li in the presence or absence of 50 µM
IPTG as indicated. Cells were stained with crystal violet at 48 h
after infection.
|
|
IPTG is required for plaque formation and replication of
vA30Li.
To determine the effect of IPTG on plaque formation,
BS-C-1 cells were infected with vA30Li in the presence or absence of 50 µM IPTG. As controls, additional cells were infected with the VT7LacOI parental or vA30L/A30Li intermediate virus in the presence or
absence of 50 µM IPTG. The vT7LacOI and vA30L/A30Li viruses, each
containing the original copy of A30L, formed plaques in the presence or
absence of IPTG. In contrast, vA30Li, which contains only the inducible
copy of A30L, required IPTG for plaque formation (Fig. 4B).
To determine if inhibition of plaque formation was due to a defect in
viral replication or spread, we analyzed the yields
of cell-associated
virus in the presence or absence of IPTG under
one-step growth
conditions. The parental virus vT7LacOI and the
intermediate virus
vA30L/A30Li replicated in the presence or absence
of IPTG, whereas
replication of vA30Li virus was entirely dependent
on the addition of
IPTG (Fig.
5). Similar yields of vA30Li
were
achieved with IPTG concentrations of 25 to 200 µM IPTG (Fig.
5A).
At 50 µM IPTG, the yield and kinetics of replication of vA30Li
were similar to those of the parental vT7LacOI and the intermediate
virus vA30L/A30Li (Fig.
5B).

View larger version (11K):
[in this window]
[in a new window]
|
FIG. 5.
Effect of IPTG on yields of vA30Li. (A) BS-C-1 cells
were infected with vT7LacOI ( ), vA30L/A30Li ( ), or vA30Li ( )
at a multiplicity of 5 and incubated in the presence of 0 to 200 µM
IPTG for 24 h. All virus titers were determined by plaque assay in
the presence of 50 µM IPTG. (B) BS-C-1 cells were infected with
vT7LacOI ( ), vA30L/A30Li ( ), or vA30Li ( ) in the absence (open
symbols) or presence (filled symbols) of 50 µM IPTG. Cells were
harvested at the indicated times after infection, and the total virus
titer of each sample was determined as for panel A.
|
|
Inducible synthesis of the A30L protein.
BS-C-1 cells were
infected with vA30Li at a multiplicity of 1 or 10 and incubated for
24 h in the presence of 0 to 100 µM IPTG. In the absence of
IPTG, no A30L protein was detected in cells infected at the low or high
multiplicity of infection (Fig. 6). The
A30L protein was detected in infected cells incubated in the presence
of 10 µM IPTG. Higher amounts of A30L were synthesized when cells
were incubated in the presence of 25 µM IPTG, but no noticeable
increase was observed at higher concentrations. Thus, similar
concentrations of IPTG were required for maximal induction of A30L
protein synthesis (Fig. 6) and virus yield (Fig. 5A).

View larger version (26K):
[in this window]
[in a new window]
|
FIG. 6.
Effect of IPTG on the synthesis of the A30L protein.
BS-C-1 cells were mock infected (U) or infected with vA30Li at a
multiplicity of infection (MOI) of 1 or 10 in the presence of 0 to 100 µM IPTG. At 24 h after infection, the cells were harvested and
the proteins were analyzed by electrophoresis on a 10 to 20% gradient
polyacrylamide gel using SDS-Tricine buffer. The proteins were then
transferred to a nitrocellulose membrane and incubated with the rabbit
polyclonal A30L peptide antibody. The bands detected by
chemiluminescence are shown. The arrow points to the A30L protein.
|
|
Synthesis of viral proteins in the absence of A30L expression.
During a productive VV infection, early, intermediate, and late
proteins are synthesized consecutively. The cessation of host protein
synthesis makes it particularly easy to label and visualize the
abundant late viral proteins by SDS-PAGE. To determine the effects of
the repression of A30L expression on viral protein synthesis, BS-C-1
cells were infected with vA30Li or the parental virus vT7LacOI in the
presence or absence of IPTG. At various times, the cells were labeled
for 30 min with a mixture of [35S]methionine and
[35S]cysteine. At the end of the labeling periods,
whole-cell extracts were analyzed by SDS-PAGE and radiolabeled proteins
were visualized by autoradiography. As shown in Fig.
7A, shifts from host to early viral
proteins and from early to late viral proteins were observed in
vA30Li-infected cells in the presence or absence of IPTG. At 3 and
6 h after infection, the protein synthesis pattern of cells infected with vA30Li in the absence of IPTG was virtually identical to
that of cells infected either with vT7LacOI or with vA30Li in the
presence of IPTG. The overall patterns of proteins labeled at later
times were similar under all conditions. Nevertheless, some differences
were noted. In cells infected with vA30Li in the absence of IPTG, a
prominent labeled band of approximately 20 kDa was detected at 9 and
12 h but was much less intense at 24 h. A faint band of
similar mobility was detected maximally at 6 h after infection
with either vT7LacOI or vA30Li in the presence of IPTG (Fig. 7A). In
addition, doublet bands of approximately 14 and 25 kDa were resolved
from extracts of cells infected with vT7LacOI or vA30Li in the presence
of IPTG, but only the lower species of each doublet was detected in
extracts of cells infected with vA30Li in the absence of IPTG (Fig.
7A). These distinctive features were reproducible and could reflect
subtle differences in the synthesis, degradation, or processing of
specific proteins in cells infected with vA30Li in the absence of
inducer, but there was no general defect in viral protein synthesis.

View larger version (66K):
[in this window]
[in a new window]
|
FIG. 7.
Synthesis and processing of viral proteins. (A)
Pulse-labeling of viral proteins. BS-C-1 cells were infected with
vT7LacOI or vA30Li at a multiplicity of 10 in the presence (+) or
absence ( ) of 50 µM IPTG as indicated. Cells were labeled with a
mixture of [35S]methionine and
[35S]cysteine for 30-min periods starting at 3, 6, 9, 12, or 24 h after infection or after mock infection (U). Immediately after
labeling, the cells were washed and lysed, and the labeled proteins
were denatured with SDS and mercaptoethanol and analyzed by
electrophoresis on a 4 to 20% gradient polyacrylamide gel. An
autoradiograph is shown. Numbers on the left correspond to molecular
masses of the marker proteins. The positions of migration of proteins
that are over- or underexpressed in cells infected with vA30Li in the
absence of IPTG are indicated by an asterisk or a dash, respectively.
(B) Proteolytic processing of viral late proteins. BS-C-1 cells were
infected either with vT7LacOI in the presence (+) or absence ( ) of
100 µg of rifampin (RIF) per ml or with vA30Li in the presence (+) or
absence ( ) of 50 µg of IPTG per ml. At 6 h after infection,
the cells were pulse-labeled with a mixture of
[35S]methionine and [35S]cysteine for 30 min. Cells were either harvested immediately (pulse) or incubated with
excess unlabeled methionine for an additional 12 h (chase). The
proteins were denatured with SDS and mercaptoethanol and analyzed by
electrophoresis on a 4 to 20% gradient polyacrylamide gel and
autoradiography. The positions of migration of the major core precursor
protein (P4a and P4b) and their mature, processed forms (4a and 4b) are
shown on the right.
|
|
Effects of A30L repression on the processing of viral
proteins.
The proteolytic processing of several core proteins is
coupled to morphogenesis (15) and can be blocked by the
drug rifampin or by infection with certain mutant viruses. Indeed, the
absence of proteolytic processing has been used as an indicator of a
defect in viral morphogenesis. To investigate the effect of inhibition of A30L expression on the processing of viral proteins, we carried out
pulse-chase experiments. BS-C-1 cells were infected with vA30Li in the
presence or absence of IPTG. As a control, cells were infected with
vT7LacOI in the presence or absence of rifampin. Infected cells were
labeled for 30 min with a mixture of [35S]methionine and
[35S]cysteine at 6 h after infection (Fig. 7B).
Cells were either harvested immediately after labeling or chased for
12 h in the presence of unlabeled amino acids. Pulse-labeling
indicated that the major core precursor proteins P4a and P4b were
synthesized in similar amounts by both viruses under permissive and
nonpermissive conditions. However, repression of A30L expression
resulted in the inhibition of proteolytic processing of P4a and P4b to
4a and 4b during the chase, producing an effect similar to that caused by rifampin (Fig. 7B) and suggesting that the A30L protein is required
for assembly or morphogenesis.
Morphogenesis of vA30Li under nonpermissive conditions.
Electron microscopy was used to determine the stage at which virus
replication was blocked in the absence of A30L expression. BS-C-1 cells
were infected with vA30Li in the presence or absence of IPTG for
24 h. The cytoplasm of cells infected with vA30Li in the presence
of IPTG contained the expected range of viral structures, including
crescents, and a large number of IV and mature particles (Fig.
8B). Cells infected with vA30Li in the absence of IPTG, however, showed large electron-dense masses of viroplasm with clearly demarcated but nonmembranous borders.
Frequently, "holes" were observed, suggesting the trapping of
less-dense material within the masses. Crescent membranes appeared
normal in size and shape except for the absence of adjacent dense
viroplasm (Fig. 8A). Circular membranes characteristic of thin sections
of IV were also seen but their centers were electron lucent, indicating that the viral membranes had enclosed little or none of the dense granular viroplasm. Some of these membranes were multilayered, giving
an onion-like appearance (Fig. 8C). Although the separation of
membranes and granular viroplasm was the distinctive phenotype of this
mutant, a small minority of membrane crescents with dense granular
viroplasm and rare IV with nucleoids and aberrant mature virions were
found in some cells infected with vA30Li in the absence of IPTG (Fig.
8D). We suspect that the formation of these viral structures was due to
incomplete repression of A30L synthesis in some cells.

View larger version (189K):
[in this window]
[in a new window]
|
FIG. 8.
Electron microscopy of cells infected with vA30Li in the
presence or absence of IPTG. BS-C-1 cells were infected with vA30Li at
a multiplicity of 10 in the presence (B) or absence (A, C, and D) of 50 µM IPTG. At 24 h after infection, the cells were fixed and
prepared for transmission electron microscopy. The arrow in panel A
points to a large dense granular mass that forms in the absence of
IPTG. Abbreviations: C, crescents; nu, nucleoid within an IV.
|
|
Association of A30L protein with viroplasm and immature and mature
virus particles.
The biochemical experiments described above
indicated that the A30L protein was associated with purified virus
particles but was probably not a membrane component. Immunoelectron
microscopy was carried out to further investigate the localization of
the A30L protein in VV virions and to determine the stage at which it
associates with assembling virus particles. Because the polyclonal antibody to the C-terminal peptide of A30L was not optimal for immunoelectron microscopy, we constructed rVV vA30LiHA, in which an
influenza virus HA tag was added to the C terminus of the inducible copy of the A30L protein. BS-C-1 cells were infected with vA30LiHA in
the presence or absence of IPTG. The HA-tagged A30L protein was
visualized by incubating the ultrathin cryosections with an HA MAb
followed by protein A conjugated to colloidal gold. In cells infected
in the presence of IPTG, gold grains were seen mostly in association
with the granular masses of viroplasm and within IV in the factory
regions (Fig. 9A). There was no specific labeling of membranes. Outside the factory areas, grains could also be
seen in association with IMV and dispersed through the cytoplasm (Fig.
9B). Gold grains were more numerous on the IV than the IMV, possibly
due to decreased accessibility of the HA epitope to the antibody after
virus maturation. Gold grains were rarely seen in cells infected with
vA30LiHA in the absence of IPTG, demonstrating the specificity of the
labeling (data not shown).

View larger version (150K):
[in this window]
[in a new window]
|
FIG. 9.
Localization of the A30L protein by immunoelectron
microscopy. BS-C-1 cells were infected with vA30LiHA at a multiplicity
of 10 in the presence of 100 µg of IPTG, per ml. After 22 h, the
cells were fixed in paraformaldehyde, cryosectioned, and incubated with
MAb MHA.11 followed by rabbit anti-mouse IgG and protein A-conjugated
to colloidal gold. Fields with numerous IV and IEV are shown in panels
A and B, respectively.
|
|
 |
DISCUSSION |
Sequence comparisons indicated that the A30L ORF is conserved
among all members of the chordopoxvirus subfamily analyzed thus far.
However, there was no obvious similarity to any other protein present
in the available databases. Furthermore, analysis of the deduced amino
acid sequence of the A30L protein did not reveal any predicted
structural or functional domain that could provide a clue to its
function. Examination of the nucleotide sequence of the A30L gene did
indicate the presence of a typical late transcription initiator element
(TAAAT) overlapping the putative ATG translation initiation site.
Nuclease protection assays demonstrated that A30L was transcribed at
late times during VV infection and showed that the transcriptional
start site was at or near the predicted TAAATG motif. Western blotting
using a polyclonal serum raised against the C-terminal amino acids of
the A30L protein confirmed that A30L is a late protein with a molecular
mass of approximately 9 kDa. The A30L protein was associated with
purified IMV and could be only partially released by the detergent
NP-40 even when DTT was included, suggesting that it might be a matrix
protein located between the core and membrane. A similar location was
suggested for the protein encoded by the ORF called A4L in VV strain
Copenhagen or A5L in VV strain WR (6, 29). Immunoelectron
microscopy revealed that the A30L protein was associated with the dense
granular viroplasm in viral factories as well as the interior of IV and IMV, with no apparent membrane localization.
To investigate the role of the A30L protein in the VV replicative
cycle, we constructed vA30Li, in which the endogenous A30L gene was
replaced by an inducible copy. Synthesis of the A30L protein was
dependent on the concentration of IPTG, with no A30L protein detected
in cells infected in the absence of the inducer. Furthermore,
replication of the virus was entirely dependent on IPTG and was maximal
at IPTG concentrations that fully induced A30L expression. The myxoma
virus homolog, which is expressed late and is virion associated, also
appears to be essential as efforts to delete that gene were
unsuccessful (Jing Xin Cao and Grant McFadden, personal communication).
Our metabolic pulse-labeling experiments indicated that early and late
VV protein synthesis occurred in the absence of inducer, although some
subtle differences were noted. The most prominent of these was a band
of 20 kDa that was prominent at 9 and 12 h but was diminished at
later times after infection in cells infected with vA30Li in the
absence of inducer. A faint band of similar mobility was seen at
earlier times under permissive conditions, raising the possibility that this 20-kDa protein is normally made in low amounts. Nevertheless, there seemed to be no perturbation in the regulation of the majority of
viral proteins. There was, however, a profound inhibition of the
proteolytic processing of certain core proteins including P4a and P4b
in the absence of A30L expression. This result is typical of situations
in which virus assembly is blocked at or before the stage of formation
of IV (15).
As predicted, electron microscopy of cells infected with vA30Li in the
absence of IPTG demonstrated a striking defect in morphogenesis. The
electron micrographs revealed large masses of granular viroplasm that
were not associated with viral membranes. Interestingly, there was a
sharp boundary between the dense viroplasm and the less-dense
surrounding material, even though no membrane border was evident.
Moreover, there were apparent holes in the dense viroplasm that were
filled with less-dense material, indicating the absence of mixing.
Although crescent and circular membranes, representing thin sections of
incomplete and possibly complete spherical particles formed, the
majorities of these were devoid of granular viroplasm and appeared
empty. Some of the membranes formed concentric layers resembling an
onion. This phenotype, in which the foci of viroplasm are not
associated with membranes, is similar to that of certain genetically
unmapped temperature-sensitive mutants of the IHD-J strain of VV
described by Dales et al. (7). Viroplasmic masses and
empty crescents have also been described in cells infected with an
inducible A14L mutant under nonpermissive conditions (22,
26). However, A14L is a membrane protein, and an additional
phenotype of the A14L mutant is the accumulation of vesicles and
aberrant membranes. In addition, the normal-looking viral membranes
formed in the absence of the A30L protein were usually distant from the
masses of viroplasm, whereas they seemed to be closer in the case of
the A14L mutant. An intriguing possibility for further investigation is
that the A30L matrix protein and the A14L membrane protein interact
with each other to allow the association of viroplasm with membranes.
 |
ACKNOWLEDGMENTS |
We thank Norman Cooper for providing cells and Alonzo Garcia for
sucrose gradient fractions of purified VV.
P.S. received support from the Special Program for Microbiology of the
Brazilian National Council for Scientific Technological Development (CNPq).
 |
FOOTNOTES |
*
Corresponding author. Mailing address: 4 Center Dr.,
MSC 0445, NIH, Bethesda, MD 20892-0445. Phone: (301) 496-9869. Fax:
(301) 480-1147. E-mail: bmoss{at}nih.gov.
Present address: Sangamo BioSciences, Inc., Richmond, CA 94804.
 |
REFERENCES |
| 1.
|
Appleyard, G.,
A. J. Hapel, and E. A. Boulter.
1971.
An antigenic difference between intracellular and extracellular rabbitpox virus.
J. Gen. Virol.
13:9-17[Abstract/Free Full Text].
|
| 2.
|
Baldick, C. J., Jr., and B. Moss.
1993.
Characterization and temporal regulation of mRNAs encoded by vaccinia virus intermediate-stage genes.
J. Virol.
67:3515-3527[Abstract/Free Full Text].
|
| 3.
|
Baldick, C. J.,
J. G. Keck, and B. Moss.
1992.
Mutational analysis of the core, spacer, and initiator regions of vaccinia virus intermediate class promoters.
J. Virol.
66:4710-4719[Abstract/Free Full Text].
|
| 4.
|
Blasco, R., and B. Moss.
1992.
Role of cell-associated enveloped vaccinia virus in cell-to-cell spread.
J. Virol.
66:4170-4179[Abstract/Free Full Text].
|
| 5.
|
Boulter, E. A., and G. Appleyard.
1973.
Differences between extracellular and intracellular forms of poxvirus and their implications.
Prog. Med. Virol.
16:86-108[Medline].
|
| 6.
|
Cudmore, S.,
R. Blasco,
R. Vincentelli,
M. Esteban,
B. Sodeik,
G. Griffiths, and J. Krijnse-Locker.
1996.
A vaccinia virus core protein, p39, is membrane associated.
J. Virol.
70:6909-6921[Abstract/Free Full Text].
|
| 7.
|
Dales, S.,
V. Milovanovitch,
B. G. T. Pogo,
S. B. Weintraub,
T. Huima,
S. Wilton, and G. McFadden.
1978.
Biogenesis of vaccinia: isolation of conditional lethal mutants and electron microscopic characterization of their phenotypically expressed defects.
Virology
84:403-428[CrossRef][Medline].
|
| 8.
|
Dales, S., and L. Siminovitch.
1961.
The development of vaccinia virus in Earle's L strain cells as examined by electron microscopy.
J. Biophys. Biochem. Cytol.
10:475-503[Abstract/Free Full Text].
|
| 9.
|
Davison, A. J., and B. Moss.
1989.
The structure of vaccinia virus early promoters.
J. Mol. Biol.
210:749-769[CrossRef][Medline].
|
| 10.
|
Davison, A. J., and B. Moss.
1989.
The structure of vaccinia virus late promoters.
J. Mol. Biol.
210:771-784[CrossRef][Medline].
|
| 11.
|
DeMasi, J., and P. Traktman.
2000.
Clustered charge-to-alanine mutagenesis of the vaccinia virus H5 gene: isolation of a dominant, temperature-sensitive mutant with a profound defect in morphogenesis.
J. Virol.
74:2393-2405[Abstract/Free Full Text].
|
| 12.
|
Earl, P. L., and B. Moss.
1991.
Generation of recombinant vaccinia viruses, p. 16.17.1-16.17.16.
In
F. M. Ausubel, R. Brent, R. E. Kingston, D. D. Moore, J. G. Seidman, J. A. Smith, and K. Struhl (ed.), Current protocols in molecular biology, vol. 2. Greene Publishing Associates & Wiley Interscience, New York, N.Y.
|
| 13.
|
Grimley, P. M.,
E. N. Rosenblum,
S. J. Mims, and B. Moss.
1970.
Interruption by rifampin of an early stage in vaccinia virus morphogenesis: accumulation of membranes which are precursors of virus envelopes.
J. Virol.
6:519-533[Abstract/Free Full Text].
|
| 14.
|
Hiller, G., and K. Weber.
1985.
Golgi-derived membranes that contain an acylated viral polypeptide are used for vaccinia virus envelopment.
J. Virol.
55:651-659[Abstract/Free Full Text].
|
| 15.
|
Katz, E., and B. Moss.
1970.
Formation of a vaccinia virus structural polypeptide from a higher molecular weight precursor: inhibition by rifampicin.
Proc. Natl. Acad. Sci. USA
6:677-684.
|
| 16.
|
Morgan, C.,
S. Ellison,
H. Rose, and D. Moore.
1954.
Structure and development of viruses observed in the electron microscope. II. Vaccinia and fowl pox viruses.
J. Exp. Med.
100:301-310[Abstract].
|
| 17.
|
Moss, B.
1996.
Poxviridae: the viruses and their replication, p. 2637-2671.
In
B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Fields virology, 3rd ed., vol. 2. Lippincott-Raven Publishers, Philadelphia, Pa.
|
| 18.
|
Moss, B.,
E. N. Rosenblum,
E. Katz, and P. M. Grimley.
1969.
Rifampicin: a specific inhibitor of vaccinia virus assembly.
Nature
224:1280-1284[Medline].
|
| 19.
|
Nagayama, A.,
B. G. T. Pogo, and S. Dales.
1970.
Biogenesis of vaccinia: separation of early stages from maturation by means of rifampicin.
Virology
40:1039-1051[CrossRef][Medline].
|
| 20.
|
Payne, L. G.
1980.
Significance of extracellular virus in the in vitro and in vivo dissemination of vaccinia virus.
J. Gen. Virol.
50:89-100[Abstract/Free Full Text].
|
| 21.
|
Rodriguez, J. R.,
C. Risco,
J. L. Carrascosa,
M. Esteban, and D. Rodriguez.
1997.
Characterization of early stages in vaccinia virus membrane biogenesis: implications of the 21-kilodalton protein and a newly identified 15-kilodalton envelope protein.
J. Virol.
71:1821-1833[Abstract].
|
| 22.
|
Rodriguez, J. R.,
C. Risco,
J. L. Carrascosa,
M. Esteban, and D. Rodriguez.
1998.
Vaccinia virus 15-kilodalton (A14L) protein is essential for assembly and attachment of viral crescents to virosomes.
J. Virol.
72:1287-1296[Abstract/Free Full Text].
|
| 23.
|
Schmelz, M.,
B. Sodeik,
M. Ericsson,
E. J. Wolffe,
H. Shida,
G. Hiller, and G. Griffiths.
1994.
Assembly of vaccinia virus: the second wrapping cisterna is derived from the trans Golgi network.
J. Virol.
68:130-147[Abstract/Free Full Text].
|
| 24.
|
Tooze, J.,
M. Hollinshead,
B. Reis,
K. Radsak, and H. Kern.
1993.
Progeny vaccinia and human cytomegalovirus particles utilize early endosomal cisternae for their envelopes.
Eur. J. Cell Biol.
60:163-178[Medline].
|
| 25.
|
Traktman, P.,
A. Caligiuri,
S. A. Jesty, and U. Sankar.
1995.
Temperature-sensitive mutants with lesions in the vaccinia virus F10 kinase undergo arrest at the earliest stage of morphogenesis.
J. Virol.
69:6581-6587[Abstract].
|
| 26.
|
Traktman, P.,
K. Liu,
J. DeMasi,
R. Rollins,
S. Jesty, and B. Unger.
2000.
Elucidating the essential role of the A14 phosphoprotein in vaccinia virus morphogenesis: construction and characterization of a tetracycline-inducible recombinant.
J. Virol.
74:3682-3695[Abstract/Free Full Text].
|
| 27.
|
Wang, S., and S. Shuman.
1995.
Vaccinia virus morphogenesis is blocked by temperature-sensitive mutations in the F10 gene, which encodes protein kinase 2.
J. Virol.
69:6376-6388[Abstract].
|
| 28.
|
Ward, G. A.,
C. K. Stover,
B. Moss, and T. R. Fuerst.
1995.
Stringent chemical and thermal regulation of recombinant gene expression by vaccinia virus vectors in mammalian cells.
Proc. Natl. Acad. Sci. USA
92:6773-6777[Abstract/Free Full Text].
|
| 29.
|
Williams, O.,
E. J. Wolffe,
A. S. Weisberg, and M. Merchlinsky.
1999.
Vaccinia virus WR gene A5L is required for morphogenesis of mature virions.
J. Virol.
73:4590-4599[Abstract/Free Full Text].
|
| 30.
|
Wolffe, E. J.,
D. M. Moore,
P. J. Peters, and B. Moss.
1996.
Vaccinia virus A17L open reading frame encodes an essential component of nascent viral membranes that is required to initiate morphogenesis.
J. Virol.
70:2797-2808[Abstract].
|
| 31.
|
Zhang, Y., and B. Moss.
1992.
Immature viral envelope formation is interrupted at the same stage by lac operator-mediated repression of the vaccinia virus D13L gene and by the drug rifampicin.
Virology
187:643-653[CrossRef][Medline].
|
Journal of Virology, July 2001, p. 5752-5761, Vol. 75, No. 13
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.13.5752-5761.2001
This article has been cited by other articles:
-
Chung, C.-S., Chen, C.-H., Ho, M.-Y., Huang, C.-Y., Liao, C.-L., Chang, W.
(2006). Vaccinia Virus Proteome: Identification of Proteins in Vaccinia Virus Intracellular Mature Virion Particles. J. Virol.
80: 2127-2140
[Abstract]
[Full Text]
-
Chiu, W.-L., Szajner, P., Moss, B., Chang, W.
(2005). Effects of a Temperature Sensitivity Mutation in the J1R Protein Component of a Complex Required for Vaccinia Virus Assembly. J. Virol.
79: 8046-8056
[Abstract]
[Full Text]
-
Resch, W., Weisberg, A. S., Moss, B.
(2005). Vaccinia Virus Nonstructural Protein Encoded by the A11R Gene Is Required for Formation of the Virion Membrane. J. Virol.
79: 6598-6609
[Abstract]
[Full Text]
-
Mercer, J., Traktman, P.
(2005). Genetic and Cell Biological Characterization of the Vaccinia Virus A30 and G7 Phosphoproteins. J. Virol.
79: 7146-7161
[Abstract]
[Full Text]
-
Punjabi, A., Traktman, P.
(2005). Cell Biological and Functional Characterization of the Vaccinia Virus F10 Kinase: Implications for the Mechanism of Virion Morphogenesis. J. Virol.
79: 2171-2190
[Abstract]
[Full Text]
-
da Fonseca, F. G., Weisberg, A. S., Caeiro, M. F., Moss, B.
(2004). Vaccinia Virus Mutants with Alanine Substitutions in the Conserved G5R Gene Fail To Initiate Morphogenesis at the Nonpermissive Temperature. J. Virol.
78: 10238-10248
[Abstract]
[Full Text]
-
Szajner, P., Weisberg, A. S., Moss, B.
(2004). Evidence for an Essential Catalytic Role of the F10 Protein Kinase in Vaccinia Virus Morphogenesis. J. Virol.
78: 257-265
[Abstract]
[Full Text]
-
Szajner, P., Weisberg, A. S., Moss, B.
(2004). Physical and Functional Interactions between Vaccinia Virus F10 Protein Kinase and Virion Assembly Proteins A30 and G7. J. Virol.
78: 266-274
[Abstract]
[Full Text]
-
Castro, A. P. V., Carvalho, T. M. U., Moussatche, N., Damaso, C. R. A.
(2003). Redistribution of Cyclophilin A to Viral Factories during Vaccinia Virus Infection and Its Incorporation into Mature Particles. J. Virol.
77: 9052-9068
[Abstract]
[Full Text]
-
Szajner, P., Jaffe, H., Weisberg, A. S., Moss, B.
(2003). Vaccinia Virus G7L Protein Interacts with the A30L Protein and Is Required for Association of Viral Membranes with Dense Viroplasm To Form Immature Virions. J. Virol.
77: 3418-3429
[Abstract]
[Full Text]
-
Chiu, W.-L., Chang, W.
(2002). Vaccinia Virus J1R Protein: a Viral Membrane Protein That Is Essential for Virion Morphogenesis. J. Virol.
76: 9575-9587
[Abstract]
[Full Text]
-
Szajner, P., Weisberg, A. S., Moss, B.
(2001). Unique Temperature-Sensitive Defect in Vaccinia Virus Morphogenesis Maps to a Single Nucleotide Substitution in the A30L Gene. J. Virol.
75: 11222-11226
[Abstract]
[Full Text]